Cellectar Biosciences (NASDAQ:CLRB) vs. ResMed (NYSE:RMD) Financial Contrast

Cellectar Biosciences (NASDAQ:CLRB) and ResMed (NYSE:RMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Insider & Institutional Ownership

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cellectar Biosciences and ResMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-298.05%	-144.59%
ResMed	27.53%	25.20%	18.55%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cellectar Biosciences and ResMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1	0	2	0	2.33
ResMed	0	5	9	1	2.73

ResMed has a consensus target price of $295.17, indicating a potential upside of 34.33%. Given ResMed’s stronger consensus rating and higher possible upside, analysts clearly believe ResMed is more favorable than Cellectar Biosciences.

Volatility and Risk

Cellectar Biosciences has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, ResMed has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cellectar Biosciences and ResMed”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79 million	($9.53)	-0.29
ResMed	$5.15 billion	6.22	$1.40 billion	$10.11	21.73

ResMed has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

ResMed beats Cellectar Biosciences on 13 of the 14 factors compared between the two stocks.

About Cellectar Biosciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.